Delivery Order SPE2DB22D3501-SPE2DB25FWS71
- Not listed
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ibrance 100 mg capsules (21-count packaging) at a ceiling value of $8,122.48 under a firm fixed-price contract. This is a non-set-aside competitive award with a completion date of September 2, 2025, and represents a child contract under AmerisourceBergen's larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 29, 2025, with completion expected by September 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibrance 125 mg capsules (21-count packages). The contract, with a completion date of September 30, 2025, represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ibrance 100 mg capsules (21-count) with a ceiling value of $8,122.48. This firm fixed-price delivery order, which must be completed by September 16, 2025, is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on August 13, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Ibrance 125 mg tablets (7-count) under a firm fixed-price contract with a ceiling value of $8,118.08 and an ultimate completion date of September 8, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $8,123.96 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Ibrance 75 mg tablets (quantity 7 units). This competitive, non-set-aside contract carries a firm fixed price and is scheduled for completion by September 5, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for the supply of Ibrance 125 mg capsules (21-count) on August 19, 2025, with completion targeted for September 10, 2025. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $8,122.48 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count units) on September 18, 2025, with completion scheduled for October 9, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ibrance 125 mg capsules (21-count units). The award is a firm fixed price contract with an ultimate completion date of October 2, 2025, and was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWS71Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) with a ceiling value of $8,123.96. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award is issued as a child contract under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999.99 billion and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, supplying an extensive portfolio of brand-name and generic medications across multiple therapeutic domains. This delivery order for Ibrance, a brand-name oncology medication, aligns with the company's established role as a prime pharmaceutical vendor supporting Defense Health Agency and other government healthcare customers. The contract reflects AmerisourceBergen's demonstrated capability to meet federal procurement requirements through open competition, with delivery orders typically structured as firm fixed-price arrangements ranging from minimal to substantial values depending on specific medical supply needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.1k | 8/4/25 |